Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Beijing Tong Ren Tang Chinese Medicine Co ( (HK:3613) ) has shared an announcement.
Beijing Tong Ren Tang Chinese Medicine Company Limited has received a traditional medicine registration license from Cambodia’s Ministry of Health, allowing its product, Tong Ren Tang Angong Niuhuang Wan, to be sold in Cambodia. This development is expected to enhance the company’s distribution channels and market expansion, although it will not immediately impact the company’s production and performance. Factors such as policy changes and market competition in Cambodia could influence future sales.
The most recent analyst rating on (HK:3613) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Beijing Tong Ren Tang Chinese Medicine Co stock, see the HK:3613 Stock Forecast page.
More about Beijing Tong Ren Tang Chinese Medicine Co
Beijing Tong Ren Tang Chinese Medicine Company Limited is a company incorporated in Hong Kong, focusing on the traditional Chinese medicine industry. It specializes in producing and distributing traditional Chinese medicinal products, with a focus on expanding its market reach.
Average Trading Volume: 1,344,539
Technical Sentiment Signal: Hold
Current Market Cap: HK$7.48B
For an in-depth examination of 3613 stock, go to TipRanks’ Overview page.